Form 4: Akero Therapeutics COO Jonathan Young Sells 10,000 Shares Under 10b5-1 Plan
SEC Form 4
Akero Therapeutics' Chief Operating Officer, Jonathan Young, sold 10,000 shares of common stock at an average price of $28.033, as part of a pre-arranged trading plan.
Summary
- Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 10,000 shares of the company's common stock on January 2, 2025.
- The sale was executed at a weighted-average price of $28.033 per share.
- The transactions were part of a pre-arranged Rule 10b5-1 trading plan adopted on June 25, 2024.
- The shares were sold in multiple transactions with prices ranging from $27.72 to $28.34.
- Following the transaction, Mr. Young directly owns 218,083 shares.
- Mr. Young also has indirect ownership of 60,000 shares held in irrevocable trusts for the benefit of his children.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of an insider stock sale under a pre-arranged plan, which is neither positive nor negative for the company's outlook.
Industry Context
This is a routine disclosure of an insider stock sale, which is common for executives of publicly traded companies. The use of a 10b5-1 plan indicates the sale was pre-planned and not based on any recent material non-public information.
Comparison to Industry Standards
- The use of a 10b5-1 trading plan is a standard practice for executives at publicly traded companies to avoid accusations of insider trading.
- Many executives at comparable biotech companies such as Madrigal Pharmaceuticals (MDGL) and Viking Therapeutics (VKTX) also utilize 10b5-1 plans for their stock transactions.
- The reported sale is within the typical range of insider transactions for executives at similar companies.
Stakeholder Impact
- The sale of shares by an executive may have a minor impact on investor sentiment, but the pre-planned nature of the sale mitigates any significant concern.
Key Dates
| Date | Description |
|---|---|
| 06/25/2024 | Date the Rule 10b5-1 trading plan was adopted by Jonathan Young. |
| 01/02/2025 | Date of the stock sale transaction. |
| 01/06/2025 | Date of the filing of the SEC Form 4. |
Keywords
Akero Therapeutics, Jonathan Young, insider trading, stock sale, Rule 10b5-1, executive, AKRO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.